Sector News

Roche’s new single-dose flu drug bolsters its case in people at high risk of complications

July 18, 2018
Life sciences

Roche’s expected Tamiflu replacement has already shown solid efficacy in otherwise healthy people. Now, a phase 3 study also showed that this new flu drug worked in people at high risk for serious flu complications, padding the drug’s case of helping Roche reclaim ground lost to Tamiflu generics.

Baloxavir marboxil, marketed in Japan as Xofluza, bested placebo in time to improvement of influenza symptoms in the phase 3 study, meeting its primary endpoint. It also demonstrated superior efficacy compared to Tamiflu in some secondary endpoints, including time to stop virus release and reducing viral levels in the body.

“Baloxavir marboxil is the first antiviral to show a clinically meaningful benefit in people who are most susceptible to complications from the flu, including older people and those living with certain medical conditions,” said Sandra Horning, M.D., Genentech’s chief medical officer and head of global product development, in a statement.

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The CAPSTONE-2 study enrolled over 2,000 participants defined by the CDC as at high risk of flu complications that can lead to hospitalization or even death. They include people 65 years or older and those who suffer from diseases like asthma, diabetes and heart disease.

However, in that Tuesday release, Genentech didn’t specify whether Xofluza was better than Tamiflu at quickly relieving flu symptoms or at reducing the rate of flu complications in those vulnerable patients. In its previous phase 3 trial in flu patients who were otherwise healthy, Xofluza didn’t significantly reduce the duration of symptoms compared to Tamiflu. Xofluza does have a dosing advantage, having achieved those benefits with a single dose, compared to Tamiflu’s twice-daily, five-day regimen.

RELATED: The first single-dose flu drug nod could be FDA’s Christmas present for Roche

The FDA is accelerating review on the drug’s use in uncomplicated influenza based on the CAPSTONE-1 study, with a decision set for Dec. 24. If approved, it will be the first flu drug with a novel mechanism of action in nearly 20 years. Horning said the company will submit the new phase 3 results to drug regulators to discuss next steps.

Genentech obtained commercial rights to Xofluza through a 2016 licensing deal with its developer Shionogi, which holds rights to the drug in Japan and Taiwan, as well as certain co-promotion rights in the U.S.

On Roche’s first-quarter earnings call, pharmaceuticals division chief Dan O’Day said Xofluza “has the potential to become a full replacement for Tamiflu.” Roche needs the Tamiflu follow-on to fill the sales gap widened by Tamiflu generics. In 2017, the first full year Tamiflu suffered copycat erosion, Tamiflu sales plummeted 33% to CHF 535 million ($537 million). The past severe flu season likely expanded the entire patient base and helped Tamiflu achieve a 11% year-over-year increase in first-quarter sales.

By: Angus Liu

Source: Fierce Pharma

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach